Trial of CPX-351 in Newly Diagnosed Elderly AML Patients
This study has been completed.
Information provided by (Responsible Party):
First received: November 10, 2008
Last updated: July 25, 2016
Last verified: July 2016
No Study Results Posted on ClinicalTrials.gov for this Study
|Study Status:||This study has been completed.|
|Study Completion Date:||December 2011|
|Primary Completion Date:||June 2010 (Final data collection date for primary outcome measure)|
|Certification or Request for Extension to Delay Results Received:||May 16, 2012|
Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Lancet JE, Cortes JE, Hogge DE, Tallman MS, Kovacsovics TJ, Damon LE, Komrokji R, Solomon SR, Kolitz JE, Cooper M, Yeager AM, Louie AC, Feldman EJ. Phase 2 trial of CPX-351, a fixed 5:1 molar ratio of cytarabine/daunorubicin, vs cytarabine/daunorubicin in older adults with untreated AML. Blood. 2014 May 22;123(21):3239-46. doi: 10.1182/blood-2013-12-540971.